TNKS and bone cancer: Tankyrase, a PARP family member, is known to bind and degrade this negative YAP/TAZ regulatory protein, and tankyrase inhibition was demonstrated to stabilize AMOT and reduce YAP/TAZ nuclear translocation and TEAD target gene expression, potentially offering a therapeutic option in these bone cancers [264,265] (Figure 4).